Dendritic cells (DCs) are versatile elements of the immune system and are best known for
their unparalleled ability to initiate and modulate adaptive immune responses. During the …

Advances in the understanding of the immunoregulatory functions of dendritic cells (DCs) in
animal models and humans have led to their exploitation as anticancer vaccines. Although …

Dendritic cells (DCs) occupy a central position in the immune system, orchestrating a wide
repertoire of responses that span from the development of self-tolerance to the elicitation of …

Dendritic cells (DCs) are the most potent professional antigen-presenting cells, capable of
initiating proper adaptive immune responses. Although tumor-infiltrating DCs are able to …

As the most potent professional antigen presenting cells, dendritic cells (DCs) have the
ability to activate both naive CD4 and CD8 T cells. Recognized for their exceptional ability to …

The discovery that dendritic cells (DC) play a key role in regulating antitumor immunity has
prompted considerable efforts in developing DC-based cancer vaccines for use in clinical …

Dendritic cells (DCs) have shown great potential as a component or target in the landscape
of cancer immunotherapy. Different in vivo and ex vivo strategies of DC vaccine generation …

Dendritic cell (DC) based cancer immunotherapy aims at the activation of the immune
system, and in particular tumor-specific cytotoxic T lymphocytes (CTLs) to eradicate the …

Dendritic cells (DCs) play a pivotal role in the orchestration of immune responses, and are
thus key targets in cancer vaccine design. Since the 2010 FDA approval of the first cancer …

Throughout the last decades, dendritic cell (DC)-based anti-tumor vaccines have proven to
be a safe therapeutic approach, although with inconsistent clinical results. The functional …